Mersana Says FDA Lifts Clinical Hold on Gastric-Cancer Treatment Phase I Trial
Provided by
Dow Jones
By Rob Curran
Biotech company Mersana Therapeutics said the Food and Drug Administration lifted a clinical hold on a Phase 1 trial of one of its cancer-treatment candidates.
In March, Mersana said the Food and Drug Administration had issued a clinical hold on the early-stage trial of the gastric-cancer drug candidate because of serious adverse effects.
Based on a review of data, Mersana lowered the starting dose in the Phase 1 dose escalation design, the company said.
In July, Mersana Therapeutics launched a broad restructuring following the failure of its lead product candidate in a late-stage study.
Write to Rob Curran at rob.curran@wsj.com
(END) Dow Jones Newswires
October 31, 2023 08:52 ET (12:52 GMT)
Copyright (c) 2023 Dow Jones & Company, Inc.-
How Anti-Obesity Drugs Are Innovating the Healthcare Market
-
What’s Happening In the Markets This Week
-
Why Immigration Has Boosted Job Gains and the Economy
-
What to Invest in During High Inflation
-
Never Mind Market Efficiency: Are the Markets Sensible?
-
Starbucks Stock Could Use a Pick-Me-Up After Big Selloff; Is it a Buy?
-
5 Cheap Stocks to Buy From an Attractive Part of the Market
-
Markets Brief: All Eyes On Inflation
-
After Earnings, Is Lyft Stock a Buy, a Sell, or Fairly Valued?
-
8 Stock Picks in the Apparel Industry
-
Baidu Earnings: Advertising Weakness Offset by Continued Growth In Cloud Business
-
Going Into Earnings, Is Target Stock a Buy, a Sell, or Fairly Valued?
-
Walmart Earnings: Low Prices and Strong Digital Presence Drive Market Share Gains
-
After Earnings and a Big Selloff, Is Shopify Stock a Buy, a Sell, or Fairly Valued?
-
Cisco Earnings: Positive Guidance and Splunk Inclusion Align With Our Long-Term Thesis
-
3 Warren Buffett Stocks to Buy After Berkshire Hathaway’s Just-Released 13F Filing